MedTrace Logo

Surfactant for Neonate With Acute Respiratory Distress Syndrome (ARDS)

NCT03217162 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-10-25

No results posted yet for this study

Summary

Acute respiratory distress syndrome (ARDS) in neonates has been defined, the role of surfactant is not clear. This study aimed to determine whether ARDS neonate would benefit from surfactant when oxygenation deteriorated on mechanical ventilation and to identify any potential risk factors related to mortality.

Conditions

  • ARDS
  • RDS
  • Surfactant

Interventions

DRUG

surfactant combined with mechanical ventilation (MV)

surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS

DRUG

mechanical ventilation (MV)

mechanical ventilation (MV) is given to the infant with ARDS

Sponsors & Collaborators

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    lead OTHER

Principal Investigators

  • Shi Yuan, PhD,MD · Children's Hospital of Chongqing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Minutes
Max Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03217162 on ClinicalTrials.gov